CRNX logo

Crinetics Pharmaceuticals Inc (CRNX)

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 cli...

NASDAQHealthcareBiotechnologyUSA

Company Profile

Stock Code
CRNX
ISIN Code
US22663K1079
Currency
US Dollar (USD)
IPO Date
2018-07-18

Contact Information

Company Address
6055 Lusk Boulevard, San Diego, CA, United States, 92121
Contact Phone
858 450 6464
Company Website
https://www.crinetics.com
Fiscal Year End
December

Financial Highlights

Market Capitalization
$999,999.99
Gross Profit (TTM)
$-999,999.99
Return on Assets (TTM)
-26.28%
EBITDA
$-999,999.99
Revenue (TTM)
$999,999.99